Septerna (NASDAQ:SEPN) SVP Daniel Long Sells 3,333 Shares

Septerna, Inc. (NASDAQ:SEPN) SVP Daniel Long sold 3,333 shares of Septerna stock in a transaction on Wednesday, July 1st. The stock was sold at an average price of $34.36, for a total transaction of $114,521.88. Following the sale, the senior vice president owned 96,412 shares in the company, valued at $3,312,716.32. This represents a 3.34% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Septerna Stock Down 1.8%

SEPN traded down $0.61 on Thursday, reaching $34.00. The company had a trading volume of 475,806 shares, compared to its average volume of 340,206. Septerna, Inc. has a 1 year low of $10.62 and a 1 year high of $37.99. The stock has a market capitalization of $1.53 billion, a PE ratio of -41.97 and a beta of 2.28. The stock has a 50-day moving average price of $29.73 and a 200-day moving average price of $27.55.

Septerna (NASDAQ:SEPN) last issued its quarterly earnings data on Monday, May 11th. The company reported ($0.19) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.42) by $0.23. Septerna had a negative return on equity of 12.72% and a negative net margin of 49.88%.The company had revenue of $26.52 million for the quarter, compared to analyst estimates of $16.98 million. As a group, analysts expect that Septerna, Inc. will post -1.59 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research analysts have commented on SEPN shares. Raymond James Financial lifted their price target on Septerna from $47.00 to $53.00 and gave the stock a “strong-buy” rating in a research report on Monday, June 8th. Cantor Fitzgerald restated an “overweight” rating and set a $60.00 target price on shares of Septerna in a research report on Tuesday, March 10th. HC Wainwright reaffirmed a “buy” rating and issued a $40.00 target price on shares of Septerna in a report on Wednesday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Septerna in a research note on Tuesday, April 21st. Finally, Guggenheim lowered their price objective on shares of Septerna from $52.00 to $45.00 and set a “buy” rating on the stock in a research report on Wednesday. One research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Septerna currently has an average rating of “Moderate Buy” and a consensus target price of $45.89.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of SEPN. Goldman Sachs Group Inc. increased its holdings in shares of Septerna by 86.6% in the fourth quarter. Goldman Sachs Group Inc. now owns 2,715,129 shares of the company’s stock valued at $75,698,000 after purchasing an additional 1,260,409 shares during the period. Janus Henderson Group PLC acquired a new stake in shares of Septerna during the first quarter worth $21,334,000. First Light Asset Management LLC purchased a new position in Septerna in the 4th quarter valued at $17,308,000. Primecap Management Co. CA purchased a new position in Septerna in the 4th quarter valued at $15,225,000. Finally, Perceptive Advisors LLC acquired a new position in Septerna in the 2nd quarter valued at $5,723,000.

Septerna Company Profile

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. GPCRs are the largest and most diverse family of cell membrane receptors and regulate physiological processes in nearly every organ system of the human body.